Endomyocardial Biopsy Market: as the 2024 ACC Expert Consensus Decision Pathway on Myocarditis establishes EMB as the standard of care at advanced heart failure centres and creates mandatory EMB indications for immune checkpoint inhibitor-associated myocarditis that expand the cardio-oncology centre as a new institutional procurement point, so the ISHLT 2025 Annual Report confirming increasing adult heart transplant recipient volumes from 2018 through 2024 generates serial post-transplant rejection surveillance biopsy demand that provides the structural revenue floor growing with transplant volume, and so cardiac MRI T1/T2 mapping and late gadolinium enhancement providing non-invasive tissue characterisation at centres with CMR expertise constrains native heart EMB procedure volume growth at experienced imaging centres.

The global endomyocardial biopsy market size was USD 182.4 Million in 2025 and is expected to register a revenue CAGR of 7.0% during the forecast period. Market revenue growth is supported by factors such as the 2024 American College of Cardiology Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis establishing EMB as the standard of care for myocarditis evaluation at advanced heart failure centres, the sustained global heart transplantation procedure volume documented in the ISHLT 2025 Annual Report generating serial EMB-based rejection surveillance demand, as well as the growing use of immune checkpoint inhibitor immunotherapy drugs creating a new and growing EMB indication for cardiac toxicity evaluation in cancer patients developing ICI-associated myocarditis. The first driving factor is the 2024 ACC Expert Consensus Decision Pathway published in the Journal of the American College of Cardiology, which defines the multidisciplinary myocarditis team as requiring performance of EMB of native and transplanted hearts with voltage-guidance capability and histopathological assessment using immunohistochemistry and viral PCR testing, and specifies fulminant myocarditis, haemodynamically unstable myocarditis, and immune checkpoint inhibitor-associated myocarditis as high-priority mandatory EMB indications where tissue diagnosis is clinically required rather than optional. The second driving factor is the ISHLT 2025 Annual Report from the International Thoracic Organ Transplant Registry, covering heart transplantations from 1992 to 2024 based on data from 12 global partners, confirming that adult heart transplant recipient volumes increased from 2018 through 2024 with the opioid crisis in the United States cited as a major contributor to elevated US solid organ transplant volumes, with standard post-transplant rejection surveillance protocols performing 5 to 15 EMB procedures per recipient in the first post-transplant year. The third driving factor is the AHA 2024 documentation that heart failure affects approximately 6.7 million Americans aged 20 and older, with inflammatory cardiomyopathy and myocarditis representing a clinically significant diagnostically challenging subset for which ACC guidelines now recommend EMB evaluation at qualifying advanced heart failure centres. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way the ACC 2024 pathway creates a binary classification of advanced heart failure centres qualifying for EMB capability versus those that do not, which drives referral consolidation of complex myocarditis cases to EMB-capable centres in a manner that increases per-centre bioptome procedure volume and procurement without requiring new centre entry into the EMB market. Once a cardiac centre qualifies under the ACC 2024 pathway criteria as an advanced heart failure programme with voltage-guided EMB capability, histopathological assessment infrastructure, and multidisciplinary cardiac pathology expertise, it becomes the designated referral destination for fulminant and immune checkpoint inhibitor-associated myocarditis cases from non-EMB-capable centres in its regional catchment area, generating a volume concentration that compounds bioptome procurement at the qualifying advanced heart failure centre without the market expanding to new institutional procurement points beyond the existing advanced centre network. As a result, the EMB market revenue trajectory is more dependent on per-centre procedure volume growth at established cardiac catheterisation laboratory accounts than on new institutional market entry, and the forecast tilts toward Argon Medical Devices maintaining its dominant bioptome market position at established advanced heart failure and transplant centre accounts. For instance, in April 2026, the ISHLT published its 2026 Annual Report in the Journal of Heart and Lung Transplantation covering heart transplant data from 15 contributing Registry partners with four focus theme articles on trends and survival by recipient sex across adult and paediatric heart transplantation, confirming continued transplant programme volume growth that sustains the post-transplant EMB surveillance demand floor. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis, published in the Journal of the American College of Cardiology, which creates a binary institutional classification of advanced heart failure centres capable of performing EMB with voltage guidance and histopathological assessment versus non-qualifying centres, and establishes that fulminant myocarditis, haemodynamically unstable myocarditis, and immune checkpoint inhibitor-associated myocarditis are mandatory EMB indications where tissue diagnosis is clinically required. This works only at centres maintaining EMB capability with experienced interventional cardiology operators, cardiac catheterisation laboratory infrastructure, and cardiac pathology expertise covering immunohistochemistry and viral PCR testing, and as the pathway requires that complex myocarditis cases including ICI-associated presentations should be managed at qualifying advanced heart failure centres, it drives referral consolidation to EMB-capable programmes that increases per-centre procedure volume and bioptome procurement. The pathway specifies that an advanced heart failure centre managing myocarditis should maintain multidisciplinary expertise encompassing interventional cardiology, cardiothoracic surgery, heart failure specialists, cardiac structural interventionalists, infectious diseases, clinical immunology, genetics counsellors, and cardiac pathologists, establishing the minimum institutional infrastructure required for EMB-based myocarditis evaluation. The growing use of immune checkpoint inhibitor immunotherapy drugs across expanding oncology indications, documented through multiple oncology publications through 2024, creates a new and growing EMB indication at oncology and cardio-oncology centres where ICI-associated myocarditis carries a reported mortality of 25 to 50% in published series, making tissue diagnosis clinically mandatory for cardiac toxicity characterisation at centres managing cancer patients developing suspected ICI myocarditis. Terumo partnered with Argon Medical in May 2022 to deliver advanced interventional cardiac solutions including bioptome products through Terumo's Indian commercial network, reflecting geographic expansion of EMB device commercial distribution into Asia Pacific markets. The effect on the market is progressive EMB procedure volume growth at qualifying advanced heart failure centres driven by ACC pathway-directed referral consolidation and the novel ICI myocarditis indication adding cardio-oncology centre procurement as a new institutional bioptome demand source. These are some of the key factors driving revenue growth of the market.

The second driver is the ISHLT 2025 Annual Report confirmation that adult heart transplant recipient volumes increased from 2018 through 2024, with the opioid crisis in the United States cited as a major contributor to elevated US solid organ transplant volumes, each new transplant recipient representing a multi-year serial EMB surveillance programme that generates 5 to 15 bioptome procedures in the first post-transplant year and 1 to 4 additional procedures per year in subsequent years depending on rejection history. ISHLT guidelines for cardiac allograft rejection surveillance acknowledge EMB as the gold standard for acute cellular rejection diagnosis with the ISHLT Standardized Cardiac Biopsy Grading System providing the histopathological framework for rejection severity classification that guides immunosuppression management decisions, maintaining the institutional protocol commitment to EMB surveillance that sustains bioptome procurement at transplant centre cardiac catheterisation laboratories independent of annual transplant volume fluctuations. The April 2026 ISHLT 2026 Annual Report in the Journal of Heart and Lung Transplantation, covering heart transplant data from 15 contributing Registry partners with four focus theme articles on trends and survival by recipient sex, confirms continued transplant programme volume data collection and recipient outcomes tracking that sustains the evidence base for EMB-based rejection surveillance protocol guidelines at cardiac transplant programmes globally. Post-transplant EMB surveillance at major transplant centres including Cleveland Clinic, Mayo Clinic, Columbia University Medical Center, Stanford Health Care, and equivalent European transplant programmes generates the highest per-centre annual bioptome procurement volume in the EMB market, with each centre performing 200 to 600 surveillance EMBs per year across its active post-transplant recipient population. The effect on the market is a structural revenue floor for EMB bioptome demand that grows with heart transplant programme volume, providing predictable and growing recurring procurement from established transplant centre accounts that sustains market revenue regardless of annual variation in myocarditis case volume. These are some of the key factors driving revenue growth of the market.

The ISHLT 2025 Annual Report confirms adult heart transplant recipient volumes increased from 2018 through 2024, with the opioid crisis in the United States cited as a major contributor to elevated US transplant volumes. Standard post-cardiac transplant rejection surveillance protocols perform 5 to 15 EMB procedures per recipient in the first post-transplant year, creating a structural per-recipient bioptome consumption pattern of predictable recurring revenue for manufacturers at transplant volume-driven institutional accounts.

The third driver is the emergence of the cardio-oncology centre as a new institutional procurement point for bioptome devices driven by the ACC 2024 pathway designation of ICI-associated myocarditis as a mandatory EMB indication, creating demand from oncology and cardio-oncology programmes that did not have EMB bioptome procurement as a structured procurement need five years ago. ICI-associated myocarditis, arising as a cardiac immune toxicity adverse event from programmed death-1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor therapies used in melanoma, lung cancer, renal cell carcinoma, and other oncology indications, carries reported mortality of 25 to 50% in published series and represents a time-sensitive clinical emergency requiring rapid cardiac tissue diagnosis to guide immunosuppression management decisions. As checkpoint inhibitor therapy use expands across oncology indications, the number of cancer patients experiencing ICI-associated myocarditis grows proportionally, creating an expanding cardio-oncology EMB procedure volume that adds to rather than substitutes for the existing transplant surveillance and fulminant myocarditis EMB demand. The April 2026 ISHLT 2026 Annual Report in the Journal of Heart and Lung Transplantation, expanding registry coverage to 15 global partners from 12 partners in the 2025 report, provides updated transplant volume data with four sex-stratified outcomes analysis focus theme articles that establish continued transplant programme volume growth context supporting post-transplant EMB surveillance market demand assessment. The effect on the market is a dual growth mechanism where transplant surveillance provides the structural demand floor growing with transplant volume and ICI myocarditis provides a novel growing procedure indication at cardio-oncology centres that compounds bioptome procurement above the transplant volume growth rate. These are some of the key factors driving revenue growth of the market.

However, the endomyocardial biopsy market faces adoption constraints from cardiac MRI as a non-invasive myocarditis diagnostic alternative, EMB procedural risk limiting access to tertiary centres, and the small specialised addressable market that collectively constrain market expansion beyond organic transplant volume and guideline adoption growth. Because cardiac MRI T1 mapping, T2 mapping, and late gadolinium enhancement provide non-invasive tissue characterisation for myocarditis without the procedural risks of right heart catheterisation and cardiac tissue sampling, and because the ACC 2024 pathway acknowledges CMR as a complementary modality that may precede EMB at centres with CMR expertise, CMR adoption at cardiac imaging centres reduces the total EMB procedure rate per myocarditis case at institutions where CMR results can preclude tissue confirmation in non-fulminant presentations. EMB procedural risks including cardiac perforation, pneumothorax, cardiac tamponade, haemorrhage, arrhythmia, and atrioventricular block require experienced interventional cardiology operators and catheterisation laboratory infrastructure, limiting EMB access to tertiary and quaternary cardiac centres with dedicated heart failure and cardiac pathology expertise and preventing commercial penetration into lower-acuity cardiac care settings. The small and specialised addressable market concentrated at approximately 300 to 500 global advanced cardiac transplant and heart failure centres limits EMB device market expansion beyond the organic growth rate of heart transplant volume and myocarditis guideline adoption, with the market scaling through per-centre volume intensity rather than through broad procedural penetration at community or regional cardiac centres. These factors substantially limit endomyocardial biopsy market growth over the forecast period.

Based on product, the global endomyocardial biopsy market is segmented into endomyocardial biopsy forceps and accessories. EMB forceps hold the largest revenue share at approximately 72% of 2025 market revenue. Bioptome forceps are the primary instruments used to obtain myocardial tissue samples from the right or left ventricle during cardiac catheterisation under fluoroscopic guidance, with jaw dimensions of 1.0 mm to 2.5 mm biopsy cup diameter and sheath compatibility from 5Fr to 7Fr. Argon Medical Devices, Cordis, and Scholten Surgical Instruments offer bioptome product families across straight, pre-curved, and maxi-curved tip configurations for right internal jugular, right subclavian, or femoral venous access approaches to right ventricular myocardial sampling. The accessories segment, encompassing guidewires, bioptome long sheaths, intravascular ultrasound guidance equipment, and pathology sample transport media kits, is expected to register the fastest revenue growth rate in the global endomyocardial biopsy market over the forecast period, driven by adoption of voltage-guided EMB procedures requiring additional cardiac mapping accessories and electro-anatomical mapping systems at centres implementing the ACC 2024 pathway voltage-guided technique requirement.

Based on end-use, the global endomyocardial biopsy market is segmented into hospitals and cardiac catheterisation laboratories, and ambulatory cardiovascular centres. Hospitals and cardiac catheterisation laboratories hold the largest revenue share, because EMB procedures require fluoroscopic guidance, experienced interventional cardiology operators, and access to cardiac pathology laboratory services for histopathological analysis that can only be provided at tertiary cardiac centre catheterisation laboratories with dedicated equipment and operator training. The approximately 300 to 500 global advanced cardiac transplant and heart failure programmes that qualify under ACC 2024 pathway criteria collectively generate the EMB bioptome procurement volume, with each centre performing 200 to 600 EMB procedures annually across its post-transplant recipient population and native heart myocarditis diagnostic caseload.

Based on regional analysis, the endomyocardial biopsy market in North America accounted for largest revenue share in 2025. The United States leads through the largest heart transplantation programme volume globally with the ISHLT 2025 Annual Report confirming opioid crisis-driven elevated US transplant volumes from 2018 through 2024, the commercial headquarters of Argon Medical Devices in Plano Texas and Teleflex in Wayne Pennsylvania creating domestic EMB forceps supply concentration, and the established cardiac catheterisation laboratory infrastructure at major US academic transplant centres including Cleveland Clinic, Mayo Clinic, Columbia Presbyterian, and Stanford that performs both post-transplant surveillance EMBs and native heart myocarditis EMBs under the clinical framework established by the ACC 2024 Expert Consensus Decision Pathway.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, France, and Spain represent the four largest national endomyocardial biopsy markets. Joline GmbH & Co. KG, a German medical device manufacturer, produces bioptome and cardiac biopsy instruments used in European cardiac catheterisation laboratories, representing the primary European-based EMB forceps manufacturer alongside the distributed commercial presence of Argon Medical Devices and Teleflex in European transplant and advanced heart failure centres. The European Association for Cardio-Thoracic Surgery and the European Heart Rhythm Association both endorse EMB as the reference standard for acute rejection diagnosis in cardiac allograft surveillance, sustaining institutional demand for bioptome procurement at European heart transplant programmes. Europe's EMB market is constrained by lower heart transplant volumes per capita relative to the United States, where the opioid crisis has driven donor availability above European levels, making the result steady rather than rapid European EMB market growth relative to North American transplant programme volume.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, South Korea, and Australia represent the four largest national endomyocardial biopsy markets. Terumo Corporation partnered with Argon Medical Devices in May 2022 to deliver interventional cardiovascular solutions including bioptome products through Terumo's Indian commercial network, reflecting commercial investment in Asia Pacific EMB device distribution as cardiac transplant programme volumes grow across the region. Japan's Heart Transplantation Study Group at the National Cerebral and Cardiovascular Centre in Suita maintains active post-transplant rejection surveillance EMB programmes following Japan's regulatory approval of cardiac transplantation in 1999 and subsequent programme expansion, leaving more room for Asia Pacific market growth than in North America where transplant programme EMB surveillance utilisation rates are already higher.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Argentina represent the two largest national endomyocardial biopsy markets. Brazil's Instituto Nacional de Cardiologia and InCor Hospital das Clínicas at the University of São Paulo operate active cardiac transplant and advanced heart failure programmes generating post-transplant EMB surveillance demand, with access to myocarditis diagnostic EMB constrained by the limited number of qualified cardiac pathology laboratories capable of performing immunohistochemistry and viral PCR analysis on cardiac biopsy specimens. The indirect effects of Iran-US sanctions and Strait of Hormuz supply chain disruptions have maintained elevated import costs for specialty cardiovascular device components entering Brazilian healthcare procurement channels through 2026, suppressing per-centre bioptome procurement volumes at Latin American transplant programmes where device cost sensitivity is higher relative to established North American and European cardiac programmes.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary GCC markets where cardiac transplant programmes at King Faisal Specialist Hospital in Riyadh and Sheikh Khalifa Medical City in Abu Dhabi generate EMB device demand. South Africa is the most established African country for advanced cardiac intervention at Groote Schuur Hospital in Cape Town and Milpark Hospital in Johannesburg, where heart transplant programmes established since the 1960s generate the most sustained EMB bioptome procurement demand on the African continent.